Cambridge Heart Inc. (OTC:CAMH) enrolled the first participants in a clinical trial of its Microvolt T-Wave Alternans test for detecting ischemia, or restricted blood flow, in patients with coronary artery disease.
The 200-patient MTWA-CAD study is designed to determine whether the test can improve the diagnosis of ischemia. The test is currently used to predict whether patients are at risk for potentially fatal arrhythmias by measuring electrical signals in the heart, according to a press release.
Cambridge Heart said it expects to complete enrollment in the trial by the middle of next year.
The company is on a bit of a roll after the Centers for Medicare and Medicaid Services handed it a win last week, allowing full reimbursement for the MTWA test when used alongside traditional cardiac stress tests. News of the clinical trial bumped CAMH stock up more than 3.5 percent, to 30 cents per share, from its 27-cent opening.